Cheung, S. Y. Amy, Evans, N. D., Chappell, M. J. (Michael J.), Godfrey, Keith, Smith, Paul J. (Paul James), 1953- and Errington, Rachel J.. (2008) Exploration of the intercellular heterogeneity of topotecan uptake into human breast cancer cells through compartmental modelling. Mathematical Biosciences, Vol.213 (No.2). pp. 119-134. ISSN 0025-5564

Preview

PDF WRAP_Evans_9871863-es-081211-finalauthorversion.pdf - Accepted Version - Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader Download (460Kb)

Abstract

A mathematical multi-cell model for the in vitro kinetics of the anti-cancer agent topotecan (TPT) following administration into a culture medium containing a population of human breast cancer cells (MCF-7 cell line) is described. This non-linear compartmental model is an extension of an earlier single-cell type model and has been validated using experimental data obtained using two-photon laser scanning microscopy (TPLSM). A structural identifiability analysis is performed prior to parameter estimation to test whether the unknown parameters within the model are uniquely determined by the model outputs. The full model has 43 compartments, with 107 unknown parameters, and it was found that the structural identifiability result could not be established even when using the latest version of the symbolic computation software MATHEMATICA. However, by assuming that a priori knowledge is available for certain parameters, it was possible to reduce the number of parameters to 81, and it was found that this (Stage Two) model was globally (uniquely) structurally identifiable. The identifiability analysis demonstrated how valuable symbolic computation is in this context, as the analysis is far too lengthy and difficult to be performed by hand. (C) 2008 Elsevier Inc. All rights reserved.

Item Type:	Journal Article
Subjects:	R Medicine > RC Internal medicine > RC0254 Neoplasms. Tumors. Oncology (including Cancer) R Medicine > RM Therapeutics. Pharmacology
Divisions:	Faculty of Science > Engineering
Library of Congress Subject Headings (LCSH):	Breast -- Cancer -- Research, Pharmacokinetics -- Mathematical models, Cancer cells
Journal or Publication Title:	Mathematical Biosciences
Publisher:	Elsevier Science Inc.
ISSN:	0025-5564
Date:	June 2008
Volume:	Vol.213
Number:	No.2
Number of Pages:	16
Page Range:	pp. 119-134
Identification Number:	10.1016/j.mbs.2008.03.008
Status:	Peer Reviewed
Publication Status:	Published
Access rights to Published version:	Restricted or Subscription Access
References:	[1] C. Bailly, Topoisomerase I poisons and suppressors as anticancer drugs, Current Medicinal Chemistry 7 (2000) p. 39-58. [2] F. Zunino, G. Pratesi, Camptothecins in clinical development, Expert Opinion on Investigational Drugs 13 (2004) p. 269–284. [3] J. O’Leary, F.M. Muggia, Camptothecins: a review of their development and schedules of administration, European Journal of Cancer 34 (1998) p. 1500-1508. [4] J.C. Wang, DNA topoisomerases, Annual Review of Biochemistry 65 (1996) p. 653-692. [5] R.J. Errington, S.M. Ammer-Beg, B. Vojnovic, L.H. Patterson, M. Zloh, P.J. Smith, Advanced microscopy solutions for monitoring the kinetics and dynamics of drug-DNA targeting in living cells, Advanced Drug Delivery Reviews 57 (2005) p. 153-167. [6] D. Yang, J.T. Strode, H.P. Spielmann, A.H.-J. Wang, T.G. Burke, DNA interactions of two clinical camptothecin drugs stabilize their active lactone forms, Journal of Americal Chemical Society 120 (1998) p. 2979-2980. [7] R.C. Robert Jr., D.W. Kufe, R.E. Pollock, R.R. Weichselbaum, J.F. Holland, III E. Frei, T.S. Gansler, editors, Cancer Medicine, Hamilton (Canada): BC Decker Inc, Fifth edition, 2000. [8] G.P. Feeney, R.J. Errington, M. Wiltshire, N. Marquez, S.C. Chappell, P.J. Smith, Tracking the cell origins for escape from topotecan action by breast cancer cells, British Journal of Cancer 88 (2003) p. 1310-1317. [9] F. Zunino, S. Dallavalle, D. Laccabue, G. Beretta, L. Merlini, G. Pratesi, Current status and perspectives in the development of camptothecins, Current Pharmaceutical Design 8 (27) (2002) p. 2505-2520. [10] M. Taron, C. Plasencia, A. Abad, C. Martin, M. Guillot, Cytotoxic effects of topotecan combined with various active G2/M-phase anticancer drugs in human tumour-derived cell lines, Investigation of New Drug 18 (2000) p. 139-147. [11] R. Alexandrova, Tumour heterogeneity, Experimental Pathology and Parasitology 4/6 (2001) p. 57-67. [12] P. Duesberg, Genetic instability of cancer cells is proportional to their degree of aneuploidy, Cell Biology 95:23 (1998) p. 13692-13697. [13] N.D. Evans, R.J. Errington, M.J. Chapman, P.J. Smith, M.J. Chappell, K.R. Godfrey, Compartmental modelling of the uptake kinetics of the anti-cancer agent topotecan in human breast cells, International Journal of Adaptive Control and Signal Processing 19 (2005), p. 395- 417. [14] N.D. Evans, R.J. Errington, M. Shelley, G.P. Feeney, M.J. Chapman, K.R. Godfrey, P.J. Smith, M.J. Chappell, A mathematical model for the in vitro kinetics of the anti-cancer agent topotecan, Mathematical Biosciences 189 (2004) p. 185-217. [15] N.D. Evans, R.J. Errington, M. Shelley, G.P. Feeney, M.J. Chapman, K.R. Godfrey, P.J. Smith, M.J. Chappell, Compartmental modeling to assess stability of topotecan bound to DNA, In: Proceedings of the 5th IFAC Symposium on Modelling and Control in Biomedical Systems, Melbourne, Australia, 21-23 August, 2003, (D. D. Feng and E. R. Carson, Eds) Pergamon, Oxford, p. 403-408. [16] A. Paradiso, A. Mangia, A. Barletta, S. Fusilli, F. Marzullo, F. Schittulli, M. De Lena, Heterogeneity of intratumour proliferative activity in primary breast cancer: biological and clinical aspects, European Journal of Cancer, 31A (6) (1995) p. 911-916. [17] M. Nugoli, P. Chuchana, J. Vendrell, B. Orsetti, L. Ursule, C. Nguyen, D. Birnbaum, E.J. Douzery, P. Cohen, C. Theillet, Genetic variability in MCF-7 sublines: evidence of rapid genomic and RNA expression profile modifications, BMC Cancer, (24 April 2003) 3:13. [18] T. Litman, M. Brangi, E. Hudson, P. Fetsch, A. Abati, D.D. Ross, K. Miyake, J.H. Resau, S.E. Bates, The multidrug-resistance phenotype associated with over expression of the new ABC half-transporter, MXR (ABCCG2), Journal of Cell Science 113 (Pt 11) (2000) p. 2011-2021. [19] I. Gryczynski, Z. Gryczynski, J.R. Lakowicz, D.Z. Yang, T.G. Burke, Fluorescence spectral properties of the anticancer drug topotecan by steady-state and frequency domain fluorometry with one-photon and multi-photon excitation, Photochemistry and Photobiology 69 (1999) p. 421-428. [20] LOCI, Laboratory for Optical and Computational Instrumentation website, multi-photon excitation fluorescence microscopy page, 2004. [21] Gonda, Neuroscience and genetic research centre, UCLA, Two photon or multiphoton laser-scanning microscopy website, 1997. [22] R. Bellman, K.J. Åström, On structural identifiability, Mathematical Biosciences 7 (1970) p. 329-339. [23] L.M. Franks, M.N. Teich, Introduction to the Cellular and Molecular Biology of Cancer, Oxford University Press, Oxford, New York, Tokyo, Third edition, 1997. [24] K.R. Godfrey, Compartmental Models and their Application, Academic Press, London, New York, 1983. [25] J.A. Jacquez, Compartmental Analysis in Biology and Medicine, BioMedware, Ann Arbor, Third edition, 1996. [26] H.P. Rang, M.M. Dale, J.M. Ritter, Pharmacology, Churchill Livingston, Edinburgh, London, New York, Fourth edition, 1999. [27] K. G. Guderley, C.-C. Hsu, A predictor-corrector method for a certain class of stiff differential equation, Mathematics of Computation 26 (1972) p. 51-69. [28] J. A. Jacquez, Modelling with Compartments, BioMedware, Ann Arbor, 1999. [29] I. Chourpa, J. M. Millot, G. D. Sockalingum, J. F. Riou, M. Manfait, Kinetics of lactone hydrolysis in antitumor drugs of camptothecin series as studied by fluorescence spectroscopy, Biochimica et Biophysica Acta 1379 (1998) p. 3353-3366. [30] M. J. Chappell, G. D. Thomas, K. R. Godfrey, A. R. Bradwell, Optimal tumor targeting by antibodies: Development of a mathematical model, Journal of Pharmacokinetics and Biopharmaceutics 19 (1991) p. 227-260. [31] E. Walter, Identifiability of State Space Models, Springer Verlag, 1982. [32] N. D. Evans, M. J. Chappell, Extensions to a procedure for generating locally identifiable reparameterisations of unidentifiable systems, Mathematical Biosciences 168 (2000) p. 137-159. [33] K. R. Godfrey, J. J. DiStefano III, Identifiability of model parameters. In E. Walter, editor, Identifiability of Parametric Models, Pergamon Press, Oxford, Chapter 1 (1987) p. 1-20. [34] M. J. Chappell, K. R. Godfrey, S. Vajda, Global identifiability of the parameters of nonlinear systems with specified inputs: A comparison of methods, Mathematical Biosciences 102 (1990) p.41-73. [35] L. Ljung and T. Glad, On global identifiability for arbitrary parametrizations, Automatica 30 (1994) p. 265-276. [36] M. P. Saccomani, S. Audoly and L. D’Angio, Parameter identifiability of nonlinear systems: the role of initial conditions, Automatica 39 (2003) p. 619-632. [37] H. Pohjanpalo, System identifiability based on the power series expansion of the solution, Mathematical Biosciences 41 (1978) p. 21-33. [38] G. Margaria, E. Riccomagno, M.J. Chappell, H.P. Wynn, Differential algebra methods for the study of the structural identifiability of rational polynomial state-space models in the biosciences, Mathematical Biosciences 174 (2001) p. 1–26. [39] S. Wolfram, The Mathematica Book (Mathematica version 5.0), Wolfram Media/Cambridge University Press, 2005. [40] AEA Technology, Facsimile (Unix version) User Guide. Harwell Laboratory: Didcot, Oxfordshire, UK, 1994. [41] F. W. Young, J. de Leeuw, T. Takane, Regression with qualitative and quantitative variables: An alternating least squares method with optimal scaling features, Psychometrika 41 (1976) p. 505-529. [42] Y. Takane, F. W. Young, J. de Leeuw, Nonmetric individual differences multidimensional scaling: An alternating least squares method with optimal scaling features, Psychometrika 42 (1977) p. 7-65. [43] M. L. Ochoa, P. B. Harrington, Detection of methamphetamine in the presence of nicotine using in situ chemical derivatization and ion mobility spectrometry, Analytical chemistry 76 (2004) p. 985-991. [44] B. Iglewicz, Some Properties of the Coefficient of Variation, Virginia Polytechnic Institute, PhD. Thesis (1967). [45] P. Leff, J. Prentice, H. Giles, G.R. Martin, J. Wood, Estimation of Agonist Affinity and Efficacy by Direct, Operational Model-Fitting, Journal of Pharmacological Methods 23 (1990) p. 225-237.
URI:	http://wrap.warwick.ac.uk/id/eprint/29709

Data sourced from Thomson Reuters' Web of Knowledge

Request changes to a record

Actions (login required)

View Item